Shots: The approval is based on P-I/II ARROW study involve assessing Gavreto (400mg, qd) n people with rearranged during transfection (RET) fusion-positive NSCLC, RET-mutant MTC, RET fusion-positive thyroid cancer, and […]readmore
Tags : Gavreto
The US FDA has approved 6 NDAs in Sept 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) […]readmore
Shots: Roche highlights data from three P-III studies across the Tecentriq (atezolizumab) TNBC programme, CNS efficacy data from integrated analyses of the pivotal Rozlytrek (entrectinib) clinical development program, and the […]readmore
Shots: The approval is based on P-I/II ARROW study assessing Gavreto (400mg, qd) in RET fusion-positive NSCLC patients with or without prior therapy, and regardless of RET fusion partner or […]readmore